Wells Fargo’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-53,652
| Closed | -$1.28M | – | 7893 |
|
|
2021
Q1 | $1.28M | Sell |
53,652
-87,041
| -62% | -$1.62M | ﹤0.01% | 4075 |
|
|
2020
Q4 | $2.05M | Sell |
140,693
-70,010
| -33% | -$928K | ﹤0.01% | 3478 |
|
|
2020
Q3 | $2.99M | Sell |
210,703
-56,100
| -21% | -$857K | ﹤0.01% | 2986 |
|
|
2020
Q2 | $3.92M | Buy |
266,803
+150,694
| +130% | +$1.53M | ﹤0.01% | 2702 |
|
|
2020
Q1 | $478K | Sell |
116,109
-106,311
| -48% | -$498K | ﹤0.01% | 4064 |
|
|
2019
Q4 | $1.07M | Buy |
222,420
+13,211
| +6% | +$72.9K | ﹤0.01% | 3818 |
|
|
2019
Q3 | $1.27M | Buy |
209,209
+3,983
| +2% | +$24.9K | ﹤0.01% | 3663 |
|
|
2019
Q2 | $1.33M | Buy |
205,226
+104,607
| +104% | +$737K | ﹤0.01% | 3667 |
|
|
2019
Q1 | $713K | Buy |
100,619
+54,341
| +117% | +$358K | ﹤0.01% | 4123 |
|
|
2018
Q4 | $224K | Buy |
46,278
+16,009
| +53% | +$83.4K | ﹤0.01% | 4840 |
|
|
2018
Q3 | $222K | Sell |
30,269
-1,033
| -3% | -$7.58K | ﹤0.01% | 4952 |
|
|
2018
Q2 | $200K | Sell |
31,302
-3,216
| -9% | -$21.3K | ﹤0.01% | 5039 |
|
|
2018
Q1 | $188K | Sell |
34,518
-19,245
| -36% | -$95.7K | ﹤0.01% | 5015 |
|
|
2017
Q4 | $225K | Buy |
53,763
+6,432
| +14% | +$38.7K | ﹤0.01% | 4903 |
|
|
2017
Q3 | $456K | Sell |
47,331
-255,477
| -84% | -$2.65M | ﹤0.01% | 4391 |
|
|
2017
Q2 | $3.58M | Buy |
302,808
+258,040
| +576% | +$3.3M | ﹤0.01% | 2710 |
|
|
2017
Q1 | $574K | Sell |
44,768
-1,974
| -4% | -$23.8K | ﹤0.01% | 4147 |
|
|
2016
Q4 | $573K | Buy |
46,742
+22,304
| +91% | +$265K | ﹤0.01% | 4103 |
|
|
2016
Q3 | $289K | Buy |
24,438
+396
| +2% | +$3.82K | ﹤0.01% | 4271 |
|
|
2016
Q2 | $209K | Buy |
24,042
+4,944
| +26% | +$33.9K | ﹤0.01% | 4385 |
|
|
2016
Q1 | $100K | Buy |
19,098
+2,406
| +14% | +$13.4K | ﹤0.01% | 4822 |
|
|
2015
Q4 | $130K | Sell |
16,692
-31,021
| -65% | -$238K | ﹤0.01% | 4735 |
|
|
2015
Q3 | $376K | Sell |
47,713
-9,652
| -17% | -$89.3K | ﹤0.01% | 4124 |
|
|
2015
Q2 | $520K | Buy |
57,365
+25,678
| +81% | +$259K | ﹤0.01% | 4064 |
|
|
2015
Q1 | $411K | Buy |
31,687
+21,757
| +219% | +$284K | ﹤0.01% | 4065 |
|
|
2014
Q4 | $135K | Sell |
9,930
-1,384
| -12% | -$15.5K | ﹤0.01% | 4621 |
|
|
2014
Q3 | $102K | Sell |
11,314
-1,947
| -15% | -$21K | ﹤0.01% | 4661 |
|
|
2014
Q2 | $180K | Buy |
13,261
+2,961
| +29% | +$30.9K | ﹤0.01% | 4417 |
|
|
2014
Q1 | $102K | Buy |
10,300
+1,900
| +23% | +$23.6K | ﹤0.01% | 4642 |
|
|
2013
Q4 | $112K | Buy |
8,400
+1,200
| +17% | +$14.6K | ﹤0.01% | 4498 |
|
|
2013
Q3 | $87K | Sell |
7,200
-7,000
| -49% | -$75K | ﹤0.01% | 4514 |
|
|
2013
Q2 | $147K | Buy |
+14,200
| New | +$196K | ﹤0.01% | 4268 |
|
Wells Fargo's GNMK Position: Q2 2021 in Review
Wells Fargo sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 53,652 shares — an estimated $1.28M sold.
Wells Fargo first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $3.92M in Q2 2020. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Wells Fargo reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Wells Fargo sold 53,652 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $1.28M.
- Wells Fargo first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- Wells Fargo's GenMark Diagnostics, Inc position peaked at $3.92M in Q2 2020.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Wells Fargo's 13F filing for Q2 2021, filed 16 Aug 2021.